“…As an important endogenous substance largely distributed in GI tract, the unconjugated bilirubin (UCB) from heme metabolism by the heme oxygenase-1 (HO-1) is an effective antioxidant ( 18 ). Our recent studies using bile duct ligated rats confirmed the critical role of unconjugated bilirubin in inactivation of digestive proteases and gut protection ( 19 , 20 ). Whereas, the specific effects of UCB on the inflammation in colitis, and the modifications of digestive proteases levels are still unrevealed.…”
Section: Introductionmentioning
confidence: 52%
“…In our previous studies, we have observed increased activities of fecal trypsin and chymotrypsin in animals with bile duct ligation (BDL) ( 19 , 20 ). From results above, UCB administrated ameliorates the tissue damage and inflammation in the gastrointestinal tract of TNBS-induced colitis.…”
Section: Discussionmentioning
confidence: 99%
“…TNBS group received colonic instillation of 1 ml of 50% ethanol in saline containing 25 mg TNBS, while the control group received 1 ml saline ( 22 , 23 ). After colonic instillation, the UCB treatment group received an intra-gastric gavages of 3.5 ml UCB (40 µM, UCB is dissolved in 0.4% dimethyl sulfoxide at concentrations up to 40 µM) ( 19 , 23 ), while the Control and TNBS groups received equal volume of saline solution. All animals were recorded daily for body weight and total feces were collected daily and stored at −4°C ( 24 ).…”
Abstract. The authors previously demonstrated that unconjugated bilirubin (UCB) may inhibit the activities of various digestive proteases, including trypsin and chymotrypsin. The digestive proteases in the lower gut are important in the pathogenesis of inflammatory bowel diseases. The effects of UCB on the inflammation and levels of digestive proteases in feces of rats with colitis have not yet been revealed. The present study investigated the effect of UCB on the inflammatory status and levels of trypsin and chymotrypsin in the feces of rats with trinitrobenzenesulfonic acid (TNBS)-induced colitis. The data indicated that treatment with TNBS resulted in a marked reduction in weight gain, which was significantly alleviated in UCB-treated rats. Furthermore, UCB treatment alleviated the inflammation induced by TNBS, detected via macroscopic damage and microscopic inflammation scores, and pro-inflammatory markers including myeloperoxidase (MPO), tumor necrosis factor (TNF)-α and interleukin (IL)-1β. Furthermore, rats with colitis demonstrated significant increases in fecal trypsin and chymotrypsin levels, whereas UCB treatment significantly alleviated these increases. A significant positive correlation was additionally revealed among the pro-inflammatory markers (MPO, TNF-α and IL-1β) and fecal digestive proteases (trypsin and chymotrypsin) in colitis. The results of the present study demonstrated that UCB ameliorated the inflammation and digestive protease increase in TNBS-induced colitis.
“…As an important endogenous substance largely distributed in GI tract, the unconjugated bilirubin (UCB) from heme metabolism by the heme oxygenase-1 (HO-1) is an effective antioxidant ( 18 ). Our recent studies using bile duct ligated rats confirmed the critical role of unconjugated bilirubin in inactivation of digestive proteases and gut protection ( 19 , 20 ). Whereas, the specific effects of UCB on the inflammation in colitis, and the modifications of digestive proteases levels are still unrevealed.…”
Section: Introductionmentioning
confidence: 52%
“…In our previous studies, we have observed increased activities of fecal trypsin and chymotrypsin in animals with bile duct ligation (BDL) ( 19 , 20 ). From results above, UCB administrated ameliorates the tissue damage and inflammation in the gastrointestinal tract of TNBS-induced colitis.…”
Section: Discussionmentioning
confidence: 99%
“…TNBS group received colonic instillation of 1 ml of 50% ethanol in saline containing 25 mg TNBS, while the control group received 1 ml saline ( 22 , 23 ). After colonic instillation, the UCB treatment group received an intra-gastric gavages of 3.5 ml UCB (40 µM, UCB is dissolved in 0.4% dimethyl sulfoxide at concentrations up to 40 µM) ( 19 , 23 ), while the Control and TNBS groups received equal volume of saline solution. All animals were recorded daily for body weight and total feces were collected daily and stored at −4°C ( 24 ).…”
Abstract. The authors previously demonstrated that unconjugated bilirubin (UCB) may inhibit the activities of various digestive proteases, including trypsin and chymotrypsin. The digestive proteases in the lower gut are important in the pathogenesis of inflammatory bowel diseases. The effects of UCB on the inflammation and levels of digestive proteases in feces of rats with colitis have not yet been revealed. The present study investigated the effect of UCB on the inflammatory status and levels of trypsin and chymotrypsin in the feces of rats with trinitrobenzenesulfonic acid (TNBS)-induced colitis. The data indicated that treatment with TNBS resulted in a marked reduction in weight gain, which was significantly alleviated in UCB-treated rats. Furthermore, UCB treatment alleviated the inflammation induced by TNBS, detected via macroscopic damage and microscopic inflammation scores, and pro-inflammatory markers including myeloperoxidase (MPO), tumor necrosis factor (TNF)-α and interleukin (IL)-1β. Furthermore, rats with colitis demonstrated significant increases in fecal trypsin and chymotrypsin levels, whereas UCB treatment significantly alleviated these increases. A significant positive correlation was additionally revealed among the pro-inflammatory markers (MPO, TNF-α and IL-1β) and fecal digestive proteases (trypsin and chymotrypsin) in colitis. The results of the present study demonstrated that UCB ameliorated the inflammation and digestive protease increase in TNBS-induced colitis.
“…; Zhou et al . ). In the light of this, the relationship between changes in the gut micro‐ecosystem and diseases has drawn more and more attention (Qin ).…”
Section: Introductionmentioning
confidence: 99%
“…Recent studies are revealing that many allergic, autoimmune and metabolic diseases in modern society are associated with changes in the gut microecosystem (Neish 2009;Nagalingam & Lynch 2011). Improved hygiene and the use of food chemical additives may induce dysbiosis of the gut microbiota, impair the activity of digestive enzymes, cause damage in gut tissue and barrier and increase infiltration of bacteria and luminal toxicants (Suez et al 2014;Chassaing et al 2015;Zhou et al 2015). In the light of this, the relationship between changes in the gut micro-ecosystem and diseases has drawn more and more attention (Qin 2015).…”
The gastrointestinal (GI) microbiota of vertebrates plays critical roles in nutrition, development, immunity and resistance against invasive pathogens. In the past decade, research of the GI microbiota of mammals has drastically increased our knowledge on the microbiota and their relationship with health and disease. However, our understanding of fish intestinal microbiota is limited. This review provides an overview of research on fish gut microbiota, including microbial composition, formation, factors that affect the GI microbes and characteristics of fish intestinal microbiota compared with human and mice. Further, the updated research on gnotobiotic zebrafish is elaborated and the insights gained on functions of the fish intestinal microbiota are discussed. Understanding the intestinal microbiota of fish will guide the development of probiotics, prebiotics and hopefully probiotic effectors as novel additives to improve the health of fish.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.